Speaker Profile

Founder & CEO, Notable Labs

Biography
Matt cofounder Notable Labs in 2014. Currently his responsibilities include leading the overall vision and strategy, partnerships, recruiting, and any other company-related matters. Previously he was as a portfolio manager and trader at Clarium Capital, a global macro hedge fund. Matt started his career on a foreign exchange and interest rate sales and trading desk at Bank of America Merrill Lynch. Matt received his BA magna cum laude in Applied Economics and Management from Cornell University where he captained the cross country team and ran the 1,500 and 5,000 meter distance for the Big Red track team.

Talk
Designing Clinical Trials For Patients Not Drugs
Randomized controlled clinical trials have changed little since their inception. Bayesian statistical methods, technologies that stratify patients, and initial success in breast cancer should make adaptive trials more common. This talk will cover how adaptive trials benefit patients by making it more likely they receive an effective drug and benefit drug companies by reducing approval time and cost.


 Session Abstract – PMWC 2020 Silicon Valley


Precision medicine has incredible promise for patients. Enormous amounts of money and time are invested in developing technologies and targeted therapies. Genomics, proteomics, phosphorylation assays, RNA expression, organoid growth, and testing, and even delicate mass measurement of liquid cancer cells are explored. This innovation must be focused to maximize the benefit to the most important participants in our healthcare system, the patient. This track is about putting patient needs first, and understanding and accessing the latest (cancer) treatment options.

  • Overview for Patients: The Latest Cancer Treatments
    In this session, you will hear from industry leaders about the latest strategies for diagnosing and treating cancer, the latest targeted- and immunotherapies, and the latest techniques for catching cancer early when it is most vulnerable. These breakthroughs could save your life or that of a loved one.
    - Jennifer Grandis, UCSF
    - Cliff Hudis, ASCO
    - Craig Lipset, Clinical Innovation Partners LLC
    - Richard Wender, American Cancer Society
  • Overview for Patients: Latest Tech In Oncology
    Oncologists are increasingly using technology to precisely diagnose the biological mechanisms driving a patient’s tumor, to predict which therapies are likely to be most effective in block-ing them, and to monitor the patient’s response in real time. Learn how these technologies are transforming the practice of oncology into a science.
    - Vik Bajaj, Foresite Capital
    - Matt De Silva, Notable Labs
    - Gary Palmer, Tempus, Inc.
    - Daniel Simon, Guardant Health
    - Margaret McCusker, Flatiron Health
  • How Patients Get What They Need
    The latest treatment options are not an option if you can’t get or afford them. Learn about the novel strategies top docs use to access breakthrough tests and therapies for their patients through clinical trials, expanded access and contingent reimbursement.
    - Eric Marton, Wavemaker 360
    - June Wasser, Consultant
    - Martin Naley, OctX
    - Conrad Vial, Sutter Health
    - Maurie Markman, CTCA Health
  • Summary for Patients: So What- Putting It Together
    For nearly a decade, non-profit Cancer Commons has helped thousands of patients and their physicians beat the odds with information about the latest tests and treatments. New software and industry partnerships are taking this to the next level, where treatment decisions are in-formed by the latest tech, a treatment’s accessibility, and the collective experience of all patients and physicians.
    - Marty Tenenbaum, Cancer Commons
    - Carla Grandori, SEngine Precision Medicine
    - Mika Newton, xCures
    - Conan Kinsey, Huntsman Cancer Center
    - Jim Snyder, Henry Ford Health System
    - Erika Monteverdi, Cancer Commons
    - Harvey Cohen, Stanford University